# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
DBV Technologies, a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunolo...
DBV Technologies Announces Plan to Implement ADS Ratio ChangeDBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stoc...
HC Wainwright & Co. analyst Andrew Fein maintains DBV Technologies (NASDAQ:DBVT) with a Buy and lowers the price target ...
DBV Technologies (NASDAQ:DBVT) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $(0....